Sabinsa Gains U.S. Patent on Garcitrin®

 PISCATAWAY, N.J.—Sabinsa Corp. was granted U.S. Patent No. 7,063,861, “Bioavailable composition of natural and synthetic HCA”, covering the use of hydroxycitric acid (HCA) in combination with garcinol—branded as Garcitrin®—for body composition and weight management. The company was previously granted two U.S. patents covering the invention and use of a unique structure of potassium salt of HCA. According to Sabinsa, Garcitrin combines another distinct composition of HCA with garcinol, a polyisoprenylated benzophenone isolated from Garcinia cambogia and Garcinia indica fruits, working to enhance the biological action of HCA and providing antioxidant activity.

Sabinsa (www.sabinsa.com) has supported scientific research into the ingredient’s safety and efficacy. One double blind clinical study involved 46 overweight females who received Garcitrin or 500 mg of calcium salt HCA for 12 weeks, maintaining their physical exercise and eating routines; the Garcitrin group reported statistically significant decreases in body weight and fat content compared to baseline values and those of the HCA only group. No adverse effects were reported.